Cele-star Biomedicine Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Sustainability
Main Product/Service
Developing medical devices for endoscopic hemostasis therapy, specifically the "Functional Powder Spraying System," which overcomes the limitations of traditional endoscopic treatments such as hemoclips, electrocautery, and epinephrine injection. During endoscopic procedures, physicians can deliver the powder directly to the lesion site through the working channel, achieving precise and effective treatment. (Same as: Cele-star Biomedicine Co., Ltd.)
The content above was translated by Ai
Founded Year
2021
Unified Business No.
91117015
Status
Active
Number of Employees
2
Total Paid-in
Capital
1,200,000 (NT$)
Location of Company
Taiwan
, Tainan City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Our company's team is led by Dr. Hsi-Chang Lin from the Department of Gastroenterology and Hepatology at National Cheng Kung University. By combining a "functional powder spray system" with "hemostatic powder," the team has developed the "Gastrointestinal Hemostatic Powder and Delivery Device System." This technology won the "18th National Innovation Award - Clinical Innovation Award" in 2021 and the "National Innovation Refinement Award" in 2022. The team will continue to optimize its product development, looking forward to successfully passing regulatory review this year to commercialize the product and benefit patients. (Also known as: EndoSurgi Biomedicine Technology Co., Ltd.)
The content above was translated by Ai